259 related articles for article (PubMed ID: 26707592)
21. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Batlevi CL; Crump M; Andreadis C; Rizzieri D; Assouline SE; Fox S; van der Jagt RHC; Copeland A; Potvin D; Chao R; Younes A
Br J Haematol; 2017 Aug; 178(3):434-441. PubMed ID: 28440559
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
Crump M; Coiffier B; Jacobsen ED; Sun L; Ricker JL; Xie H; Frankel SR; Randolph SS; Cheson BD
Ann Oncol; 2008 May; 19(5):964-9. PubMed ID: 18296419
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Robertson MJ; Kahl BS; Vose JM; de Vos S; Laughlin M; Flynn PJ; Rowland K; Cruz JC; Goldberg SL; Musib L; Darstein C; Enas N; Kutok JL; Aster JC; Neuberg D; Savage KJ; LaCasce A; Thornton D; Slapak CA; Shipp MA
J Clin Oncol; 2007 May; 25(13):1741-6. PubMed ID: 17389337
[TBL] [Abstract][Full Text] [Related]
24. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
Ma J; Xing W; Coffey G; Dresser K; Lu K; Guo A; Raca G; Pandey A; Conley P; Yu H; Wang YL
Oncotarget; 2015 Dec; 6(41):43881-96. PubMed ID: 26575169
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.
Collins GP; Eyre TA; Linton KM; Radford J; Vallance GD; Soilleux E; Hatton C
Br J Haematol; 2015 Sep; 170(6):886-90. PubMed ID: 25721307
[No Abstract] [Full Text] [Related]
26. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Genovese MC; Kavanaugh A; Weinblatt ME; Peterfy C; DiCarlo J; White ML; O'Brien M; Grossbard EB; Magilavy DB
Arthritis Rheum; 2011 Feb; 63(2):337-45. PubMed ID: 21279990
[TBL] [Abstract][Full Text] [Related]
27. Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma.
Gordon LI; Kaplan JB; Popat R; Burris HA; Ferrari S; Madan S; Patel MR; Gritti G; El-Sharkawi D; Chau I; Radford JA; Pérez de Oteyza J; Zinzani PL; Iyer S; Townsend W; Karmali R; Miao H; Proscurshim I; Wang S; Wu Y; Stumpo K; Shou Y; Carpio C; Bosch F
Clin Cancer Res; 2020 Jul; 26(14):3546-3556. PubMed ID: 32327472
[TBL] [Abstract][Full Text] [Related]
28. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Okamoto H; Kobayashi A
N Engl J Med; 2011 Jan; 364(1):83-4; author reply 84. PubMed ID: 21208113
[No Abstract] [Full Text] [Related]
29. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.
Morschhauser FA; Cartron G; Thieblemont C; Solal-Céligny P; Haioun C; Bouabdallah R; Feugier P; Bouabdallah K; Asikanius E; Lei G; Wenger M; Wassner-Fritsch E; Salles GA
J Clin Oncol; 2013 Aug; 31(23):2912-9. PubMed ID: 23835718
[TBL] [Abstract][Full Text] [Related]
30. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
Lin C; DiCioccio RA; Haykal T; McManigle WC; Li Z; Anand SM; Poe JC; Bracken SJ; Jia W; Alyea EP; Cardones AR; Choi T; Gasparetto C; Grunwald MR; Hennig T; Kang Y; Long GD; Lopez R; Martin M; Minor KK; Quinones VLP; Sung AD; Wiggins K; Chao NJ; Horwitz ME; Rizzieri DA; Sarantopoulos S
Transplant Cell Ther; 2023 Mar; 29(3):179.e1-179.e10. PubMed ID: 36577483
[TBL] [Abstract][Full Text] [Related]
31. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
Weinblatt ME; Kavanaugh A; Burgos-Vargas R; Dikranian AH; Medrano-Ramirez G; Morales-Torres JL; Murphy FT; Musser TK; Straniero N; Vicente-Gonzales AV; Grossbard E
Arthritis Rheum; 2008 Nov; 58(11):3309-18. PubMed ID: 18975322
[TBL] [Abstract][Full Text] [Related]
32. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
[TBL] [Abstract][Full Text] [Related]
33. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
Bussel J; Arnold DM; Grossbard E; Mayer J; Treliński J; Homenda W; Hellmann A; Windyga J; Sivcheva L; Khalafallah AA; Zaja F; Cooper N; Markovtsov V; Zayed H; Duliege AM
Am J Hematol; 2018 Jul; 93(7):921-930. PubMed ID: 29696684
[TBL] [Abstract][Full Text] [Related]
34. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
35. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.
Chen L; Monti S; Juszczynski P; Daley J; Chen W; Witzig TE; Habermann TM; Kutok JL; Shipp MA
Blood; 2008 Feb; 111(4):2230-7. PubMed ID: 18006696
[TBL] [Abstract][Full Text] [Related]
36. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.
Genovese MC; van der Heijde DM; Keystone EC; Spindler AJ; Benhamou C; Kavanaugh A; Fudman E; Lampl K; O'Brien C; Duffield EL; Poiley J; Weinblatt ME
J Rheumatol; 2014 Nov; 41(11):2120-8. PubMed ID: 25225285
[TBL] [Abstract][Full Text] [Related]
37. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
Cheng S; Coffey G; Zhang XH; Shaknovich R; Song Z; Lu P; Pandey A; Melnick AM; Sinha U; Wang YL
Blood; 2011 Dec; 118(24):6342-52. PubMed ID: 22025527
[TBL] [Abstract][Full Text] [Related]
38. The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Hilgendorf I; Eisele S; Remer I; Schmitz J; Zeschky K; Colberg C; Stachon P; Wolf D; Willecke F; Buchner M; Zirlik K; Ortiz-Rodriguez A; Lozhkin A; Hoppe N; von zur Muhlen C; zur Hausen A; Bode C; Zirlik A
Arterioscler Thromb Vasc Biol; 2011 Sep; 31(9):1991-9. PubMed ID: 21700926
[TBL] [Abstract][Full Text] [Related]
39. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
40. Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.
Harrington BK; Gardner HL; Izumi R; Hamdy A; Rothbaum W; Coombes KR; Covey T; Kaptein A; Gulrajani M; Van Lith B; Krejsa C; Coss CC; Russell DS; Zhang X; Urie BK; London CA; Byrd JC; Johnson AJ; Kisseberth WC
PLoS One; 2016; 11(7):e0159607. PubMed ID: 27434128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
